MAIN ARTICLE
When a commercial rebate becomes a warning sign
The ICIJ Cancer Calculus investigation describes whistleblower reports made in 2024 and 2025 alleging that Western manufacturers offered Russian intermediaries bonuses and rebates of 15 to 35 percent during 2020–2023. Investigators contrasted those figures with markets where comparable incentives reportedly rarely exceeded 10 percent. Such payments are not inherently unlawful: pharmaceutical suppliers can issue credit notes, grant volume discounts or reward prompt payment for legitimate commercial reasons. The central question is whether unusually generous margins concealed improper transfers or whether companies consciously ignored credible signs of misconduct.
Proekt also cited a confidential industry survey by the Russian auditing firm Kept showing an average bonus of about 30 percent for government-focused distributors in 2022. Kept cautioned against directly comparing those agreements with retail distribution because the channels have different structures and expenses. That distinction matters. Percentages alone cannot determine culpability; investigators would need contracts, banking records, ownership information and the precise circumstances of each tender.














